1.58
-0.07 (-4.25%)
| Penutupan Terdahulu | 1.65 |
| Buka | 1.76 |
| Jumlah Dagangan | 20,081 |
| Purata Dagangan (3B) | 12,209 |
| Modal Pasaran | 57,169,300 |
| Harga / Buku (P/B) | 4.06 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2025 - 9 May 2025 |
| Margin Operasi (TTM) | -328.15% |
| EPS Cair (TTM) | -0.890 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 142.70% |
| Nisbah Semasa (MRQ) | 0.190 |
| Aliran Tunai Operasi (OCF TTM) | -37.73 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -27.13 M |
| Pulangan Atas Aset (ROA TTM) | -24.57% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Armata Pharmaceuticals, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.50 |
|
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 70.25% |
| % Dimiliki oleh Institusi | 3.84% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Edgewood Management Llc | 31 Dec 2024 | 100,000 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 20 Mar 2025 | Pengumuman | Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update |
| 12 Mar 2025 | Pengumuman | Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva |
| 11 Mar 2025 | Pengumuman | Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |